Sign in

CIK 0002035832 · <br>Emerging growth company

Aktis Oncology, Inc.

Sign in to watch
Ticker
AKTS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
852584233
Phone
978-237-4380
Business address
17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MA, 02210
  1. 8-K Event Results of operations
  2. 10-K Report Annual Report
  3. SCHEDULE 13D Stake Beneficial Ownership Report
  4. SCHEDULE 13D Stake Beneficial Ownership Report
  5. SCHEDULE 13D Stake Beneficial Ownership Report
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market buy Director bought 232,870 shares at $18.00 ($4,191,660)
  8. 4 Open-market buy 10% owner bought 1,112,777 shares at $18.00 ($20,029,986)
  9. 4 Open-market buy 10% owner bought 1,112,777 shares at $18.00 ($20,029,986)
  10. SCHEDULE 13D Stake Beneficial Ownership Report
  11. 4 Open-market buy Director bought 2,222,222 shares at $18.00 ($39,999,996)
  12. 4 Open-market buy 10% owner bought 835,000 shares at $18.00 ($15,030,000)
  13. 4 Open-market buy Director bought 835,000 shares at $18.00 ($15,030,000)
  14. 4 Conversion Director acquired 19,631 shares (conversion)
  15. S-8 Other Securities Offered to Employees in Benefit Plans
  16. 8-K Event Bylaws or fiscal year change
  17. 424B4 Offering Prospectus
  18. EFFECT Other Notice of Effectiveness
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 2 of 4 · 70 filings